TY - JOUR
T1 - Risk Factors for Phenoconversion in Rapid Eye Movement Sleep Behavior Disorder
AU - Zhang, Hui
AU - Iranzo, Alex
AU - Högl, Birgit
AU - Arnulf, Isabelle
AU - Ferini-Strambi, Luigi
AU - Manni, Raffaele
AU - Miyamoto, Tomoyuki
AU - Oertel, Wolfgang H.
AU - Dauvilliers, Yves
AU - Ju, Yo EI
AU - Puligheddu, Monica
AU - Sonka, Karel
AU - Pelletier, Amélie
AU - Montplaisir, Jacques Y.
AU - Stefani, Ambra
AU - Ibrahim, Abubaker
AU - Frauscher, Birgit
AU - Leu-Semenescu, Smaranda
AU - Zucconi, Marco
AU - Terzaghi, Michele
AU - Miyamoto, Masayuki
AU - Janzen, Annette
AU - Figorilli, Michela
AU - Fantini, Maria L.
AU - Postuma, Ronald B.
N1 - Funding Information:
This work was supported by grants from Fonds de la recherche du Québec‐Santé and the Canadian Institutes of Health Research.
Publisher Copyright:
© 2022 American Neurological Association.
PY - 2022/3
Y1 - 2022/3
N2 - Objective: This study was undertaken to follow up predictive factors for α-synuclein–related neurodegenerative diseases in a multicenter cohort of idiopathic/isolated rapid eye movement sleep behavior disorder (iRBD). Methods: Patients with iRBD from 12 centers underwent a detailed assessment for potential environmental and lifestyle risk factors via a standardized questionnaire at baseline. Patients were then prospectively followed and received assessments for parkinsonism or dementia during follow-up. The cumulative incidence of parkinsonism or dementia was estimated with competing risk analysis. Cox regression analyses were used to evaluate the predictive value of environmental/lifestyle factors over a follow-up period of 11 years, adjusting for age, sex, and center. Results: Of 319 patients who were free of parkinsonism or dementia, 281 provided follow-up information. After a mean follow-up of 5.8 years, 130 (46.3%) patients developed neurodegenerative disease. The overall phenoconversion rate was 24.2% after 3 years, 44.8% after 6 years, and 67.5% after 10 years. Patients with older age (adjusted hazard ratio [aHR] = 1.05) and nitrate derivative use (aHR = 2.18) were more likely to phenoconvert, whereas prior pesticide exposure (aHR = 0.21–0.64), rural living (aHR = 0.53), lipid-lowering medication use (aHR = 0.59), and respiratory medication use (aHR = 0.36) were associated with lower phenoconversion risk. Risk factors for those converting to primary dementia and parkinsonism were generally similar, with dementia-first converters having lower coffee intake and beta-blocker intake, and higher occurrence of family history of dementia. Interpretation: Our findings elucidate the predictive values of environmental factors and comorbid conditions in identifying RBD patients at higher risk of phenoconversion. ANN NEUROL 2022;91:404–416.
AB - Objective: This study was undertaken to follow up predictive factors for α-synuclein–related neurodegenerative diseases in a multicenter cohort of idiopathic/isolated rapid eye movement sleep behavior disorder (iRBD). Methods: Patients with iRBD from 12 centers underwent a detailed assessment for potential environmental and lifestyle risk factors via a standardized questionnaire at baseline. Patients were then prospectively followed and received assessments for parkinsonism or dementia during follow-up. The cumulative incidence of parkinsonism or dementia was estimated with competing risk analysis. Cox regression analyses were used to evaluate the predictive value of environmental/lifestyle factors over a follow-up period of 11 years, adjusting for age, sex, and center. Results: Of 319 patients who were free of parkinsonism or dementia, 281 provided follow-up information. After a mean follow-up of 5.8 years, 130 (46.3%) patients developed neurodegenerative disease. The overall phenoconversion rate was 24.2% after 3 years, 44.8% after 6 years, and 67.5% after 10 years. Patients with older age (adjusted hazard ratio [aHR] = 1.05) and nitrate derivative use (aHR = 2.18) were more likely to phenoconvert, whereas prior pesticide exposure (aHR = 0.21–0.64), rural living (aHR = 0.53), lipid-lowering medication use (aHR = 0.59), and respiratory medication use (aHR = 0.36) were associated with lower phenoconversion risk. Risk factors for those converting to primary dementia and parkinsonism were generally similar, with dementia-first converters having lower coffee intake and beta-blocker intake, and higher occurrence of family history of dementia. Interpretation: Our findings elucidate the predictive values of environmental factors and comorbid conditions in identifying RBD patients at higher risk of phenoconversion. ANN NEUROL 2022;91:404–416.
UR - http://www.scopus.com/inward/record.url?scp=85123626154&partnerID=8YFLogxK
U2 - 10.1002/ana.26298
DO - 10.1002/ana.26298
M3 - Article
C2 - 34981563
AN - SCOPUS:85123626154
SN - 0364-5134
VL - 91
SP - 404
EP - 416
JO - Annals of neurology
JF - Annals of neurology
IS - 3
ER -